Immunohistochemical detection of female sex hormone receptors in craniopharyngiomas: correlation with clinical and histologic features

Izumoto, Shuichi; Suzuki, Tsuyosi; Kinoshita, Manabu; Hashiba, Tetsuo; Kagawa, Naoki; Wada, Kouichi; Fujimoto, Yasunori; Hashimoto, Naoya; Saitoh, Youichi; Maruno, Motohiko; Yoshimine, Toshiki

doi:10.1016/j.surneu.2004.08.094

Cited by 29 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most predictive clinical prognostic indicator of recurrence is degree of residual tumor following resection, 67,93 with adamantinomatous tumors more likely to recur than the papillary subtype. 67 Immunohistological analyses of labeling indices and sex hormone receptor expression have demonstrated inconsistent results in predicting tumor regrowth when evaluating MIB-1, 2,26,65 Ki-67, 41,55 and estrogen and progesterone receptor expression. 39,41,88 However, other molecular prognostic indicators of recurrence have demonstrated a number of gene expression patterns highlighting the difference between primary and recurrent tumors, which may be exploited in the diagnostic management of these individuals.…”

Section: Tumor Recurrencementioning

confidence: 99%

“…67 Immunohistological analyses of labeling indices and sex hormone receptor expression have demonstrated inconsistent results in predicting tumor regrowth when evaluating MIB-1, 2,26,65 Ki-67, 41,55 and estrogen and progesterone receptor expression. 39,41,88 However, other molecular prognostic indicators of recurrence have demonstrated a number of gene expression patterns highlighting the difference between primary and recurrent tumors, which may be exploited in the diagnostic management of these individuals. Compared with primary tumors, recurrent tumors display increased expression of growth factors and their receptors that normally regulate cellular proliferation, including platelet-derived growth factor receptor-a (PDGFR-a) and fibroblast growth factor-2 (FGF-2).…”

Section: Tumor Recurrencementioning

confidence: 99%

See 1 more Smart Citation

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Hussain¹,

Eloy²,

Carmel³

et al. 2013

JNS

View full text Add to dashboard Cite

show abstract

Section: Tumor Recurrencementioning

confidence: 99%

Section: Tumor Recurrencementioning

confidence: 99%

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Hussain¹,

Eloy²,

Carmel³

et al. 2013

JNS

View full text Add to dashboard Cite

show abstract

“…Craniopharyngiomas express estrogen [45] and progesterone receptor mRNA [46] and protein [47]. It has been reported that treatment of craniopharyngioma cell cultures by progesterone results in decreased [ 3 H]thymidine uptake [46].…”

Section: Pathogenesis and Pathologic Findingsmentioning

confidence: 99%

Craniopharyngiomas

Karavitaki

Wass

2008

Endocrinology and Metabolism Clinics of North America

View full text Add to dashboard Cite

show abstract

“…Nie podzielają tego zdania inni badacze, tj. Nishi, Izumoto, Haba [83][84][85]. Pojawia się też pogląd, iż wartość indeksu proliferacyjnego Ki67 w guzach nawrotowych jest istotnie statystycznie wyższa od Ki67 w guzie pierwotnym [79,80,86].…”

Section: Obraz Histopatologicznyunclassified

“…Nawroty guza obserwowano częściej u pacjentów z brakiem ekspresji receptorów ER i PR, odpowiednio 29 i 11%. Według autora pacjenci z brakiem tych receptorów powinni być leczeni bardziej agresywnie [84].…”

Section: Obraz Histopatologicznyunclassified

Craniopharyngioma – epidemiology, pathogenesis, imaging, clinical symptoms

Moszczyńska¹,

Szalecki²,

Pasternak-Pietrzak³

et al. 2017

Pediatr. Endocrinol.

View full text Add to dashboard Cite

Craniopharyngioma is a slowly growing, histologically benign tumor of the sellar region (I grade in WHO classification), there have been described rare cases of malignant transformation. It contributes to 5,6-14,1% of brain tumors in children. Incidence rate is 1,3-2,1/million/year and around 30-50% are diagnosed in children even as early as in their prenatal and neonatal period. There are 2 hypothesis of tumor etiopathology: the tumor origins from ectodermal remnants of Rathke's pouch (ameloblasticum type) or it arises from metaplasia of residual embryonal epithelium of the anterior pituitary gland and of the anterior infundibulum (papillary type). Adamantinomatous type is more frequent in children and papillary type dominates in adults. In around 50-95% of cases of adamantinomatous type an activating mutation in the gene CTNN1encoding β-catenin is present. BRAF V600E mutation is a genetic background of papillary craniopharyngioma, present in 95% of patients. The method of choice for craniopharyngioma diagnostics is MR imaging with contrast agents. The most frequent symptoms of craniopharyngioma are: increased intracranial pressure, visual disturbanSłowa kluczowe czaszkogardlak, włókna Rosenthala, p63, Ki67, szlak Wnt, bóle głowy, zaburzenia widzenia, niedoczynność przysadki, moczówka prosta StreszczenieCzaszkogardlak jest wolnorosnącym, histopatologicznie łagodnym guzem okolicy siodła tureckiego (I stopień wg klasyfikacji WHO), opisywano rzadkie przypadki złośliwej transformacji. Stanowi 5,6-14,1% guzów OUN u dzieci. Zapadalność wynosi 1,3-2,1/ mln/rok, 30-50% jest rozpoznawana w wieku dziecięcym, również w okresie prenatalnym czy noworodkowym. Dwie hipotezy podają etiopatogenezę guza: powstaje on z nabłonkowych pozostałości przewodu czaszkowo-gardłowego lub kieszonki Rathkego (typ szkliwiakowaty) albo w wyniku metaplazji resztkowych komórek nabłonka płaskiego przedniego płata przysadki i lejka (typ brodawkowaty).Typ szkliwiakowaty dominuje u dzieci, brodawkowaty u dorosłych. W 50-95% przypadków postaci szkliwiakowatej wykazano mutację aktywującą w genie CTNN1 kodującym β-kateninę. Mutacja BRAF V600E jest genetycznym podłożem wariantu brodawkowatego, stwierdzanym u 95% pacjentów. Metodą z wyboru w diagnostyce obrazowej czaszkogardlaka jest MR z kontrastem. Do typowych objawów czaszkogardlaka należą: wzmożone ciśnienie śródczaszko-we, zaburzenia widzenia, niedoczynność przysadki.

show abstract

Immunohistochemical detection of female sex hormone receptors in craniopharyngiomas: correlation with clinical and histologic features

Cited by 29 publications

References 14 publications

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies

Craniopharyngiomas

Craniopharyngioma – epidemiology, pathogenesis, imaging, clinical symptoms

Contact Info

Product

Resources

About